Global Encephalitis Vaccines Market Size and Share
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 5.20% |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Global Encephalitis Vaccines Market Analysis by Mordor Intelligence
The Global Encephalitis Vaccines Market is expected to register a CAGR of 5.2% during the forecast period.
The COVID-19 pandemic had a substantial influence on the market studied in the early months of the pandemic because people were unable to acquire planned vaccinations due to lockdowns and restrictions on non-emergency hospital visits. However, once the COVID-19 epidemic was under control in 2021, immunizations resumed, allowing the industry to regain its momentum. Several studies revealed that COVID-19 vaccination caused few occurrences of encephalitis. According to the study published in February 2022, titled "Acute encephalitis after COVID-19 vaccination: A case report and literature review" due to the current global pandemic, vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) have been distributed worldwide; nonetheless, incidences of SARS-CoV-2 vaccination-related encephalitis have been documented infrequently. Thus, due to increasing incidence of encephalitis after COVID-19 vaccination significantly impacted the market.
The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market. For instance, according to the World Health Organization as of April 28, 2022, 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 probable cases) had been documented in four Australian states. Moreover, according to the study titled "Global magnitude of encephalitis burden and its evolving pattern over the past 30 years" published in June 2022, there were 1,444,720 incident cases, 89,900 fatalities, and 4.80 million DALYs associated with encephalitis worldwide in 2019. As the number of cases and fatalities rises, individuals must take preventive measures such as immunisation, which increases demand for encephalitis vaccines, thereby boosting the market growth.
Additionally, various strategies adopted by the key market players such as product launches, mergers, and acquisitions are likely to boost the market growth. For instance, in August 2021, Pfizer Inc. revealed that the TICOVAC (tick-borne encephalitis (TBE) vaccine) was approved by the United States Food and Drug Administration (FDA) for active immunization to prevent TBE in individuals 1 year of age and older. TICOVAC is the one of the first FDA-approved vaccine to help protect United States adults and children against the TBE virus when visiting or living in TBE endemic areas.
Thus, owing to the abovementioned factors, the market is expected to project significant growth over the forecast period. However, the side effects of the vaccine and the challenges of the vaccine constrain market growth.
Global Encephalitis Vaccines Market Trends and Insights
Japanese Encephalitis Segment is Dominate the Encephalitis Vaccines Market Over the Forecast Period
The Japanese Encephalitis (JE) vaccine segment is estimated to grow at a significant rate over the forecast period. According to the study published in January 2022 titled "A Bibliometric Analysis of Global Research on Japanese Encephalitis From 1934 to 2020" JE is primarily found in 24 Southeast Asian and Western Pacific nations. Each year, roughly 68,000 clinical cases are reported, and more than 3 billion people are at risk of infection, imposing a significant burden on the population's health and the healthcare sector. Thus, with the growing incidence of Japanese encephalitis, the demand for immunization is expected to increase which is likely to propel the growth of the segment.
Furthermore, the government initiatives for the JE vaccination programs are further boosting the segment. The governments of India came up with national immunization plans that carry out mass vaccinations. For instance, in July 2022, the chief medical officer of Nainital initiated a widespread vaccination drive in private and government schools for children aged 1 to 15 years to be inoculated against Japanese Encephalitis. The marketing is witnessing strong demand for JE vaccines due to routine immunization. Therefore, the inclusion of vaccination against Japanese encephalitis in national immunization plans will act as one of the significant growth drivers for the Japanese Encephalitis (JE) vaccine segment during the forecast period.
Thus, all aforementioned factors are expected to boost the segment growth over the forecast period.
Asia-Pacific Dominate the Encephalitis Vaccines Market Over the Forecast Period
The market in Asia is expected to grow exponentially over the forecast period. Japanese encephalitis is endemic mostly in Asian countries. According to the updates from European Centre for Disease Prevention and Control in March 2022, the Japanese Encephalitis virus can be found throughout Asia and Oceania, from Japan to India, Pakistan, and Australia. Outbreaks are unpredictable, chaotic, and geographically and temporally confined events. About 30,000 to 50,000 cases are recorded each year, and the virus is a prominent cause of viral encephalitis in Asia. Thus, the growing incidence of encephalitis in the region positively impacted the market growth over the forecast period.
The organizations such as United Nations Children's Fund (UNICEF), World Health Organization (WHO), and Gavi are focusing on preventing the disease from spreading through vaccination. To ensure maximum immunization, the JE vaccines have been made mandatory for newborn children. This will provide incredible opportunities for the manufacturers catering to the region. For instance, in March 2022, the Australian government made a USD 69 million investment to combat the spread of the Japanese encephalitis virus (JEV). Program actions aim to protect people and animals most at risk during the present outbreak by preventing disease exposure through immunization and mosquito management techniques.
Furthermore, growing investment in the R&D sector, entry of new vaccine manufacturers in countries like India and China, an increasing number of travelers in the region, and medical tourism is propelling the market growth in the region.
Competitive Landscape
The encephalitis vaccine market is moderately competitive and consists of several major players. Strong manufacturing processes and significant investments in releasing improved vaccines in BRICS countries are opportunities in the market. Some of the companies which are currently dominating the market are Valneva SE., Bharat Biotech, BIKEN, Chengdu Institute of Biological Products Co., Ltd., Liaoning Cheng Bio Co., Ltd., GlaxoSmithKline Plc, Sanofi Pasteur, Tiantan Biological Product, Zhejiang Tianyuan Bio-Pharmaceutical.
Global Encephalitis Vaccines Industry Leaders
-
Valneva SE.
-
Bharat Biotech
-
BIKEN
-
Pfizer Inc.
-
GlaxoSmithKline
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- In September 2022, NSW expanded free access to the Japanese encephalitis (JE) vaccine to residents living in affected regional areas to protect those most at risk.
- In September 2021, Valneva SE stated that the United States Department of Defense (DoD) has exercised the first option under a contract signed in September 2020 to purchase further supplies of its Japanese encephalitis (JE) vaccine IXIARO.
Global Encephalitis Vaccines Market Report Scope
As per the scope of the report, encephalitis is inflammation of the brain. There are several causes, but the most common is a viral infection. Encephalitis can also cause confused thinking, seizures, or problems with senses or movement. The Encephalitis Vaccines Market is segmented by Vaccine Type (Mouse Brain-Derived Inactivated Vaccine, Cell Culture-Derived Inactivated Vaccine, Cell Culture-Derived Live Attenuated Vaccine), Indication Type (Japanese Encephalitis, Tick-Borne Encephalitis, Rabies Encephalitis), End-User (Child, and Adult), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| Mouse Brain-Derived, Inactivated Vaccine |
| Cell Culture-Derived, Inactivated Vaccine |
| Cell Culture-Derived, Live Attenuated Vaccine |
| Japanese Encephalitis |
| Tick-Borne Encephalitis |
| Rabies Encephalitis |
| Child |
| Adult |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Vaccine Type | Mouse Brain-Derived, Inactivated Vaccine | |
| Cell Culture-Derived, Inactivated Vaccine | ||
| Cell Culture-Derived, Live Attenuated Vaccine | ||
| By Type Of Indication | Japanese Encephalitis | |
| Tick-Borne Encephalitis | ||
| Rabies Encephalitis | ||
| By End-User | Child | |
| Adult | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is the current Global Encephalitis Vaccines Market size?
The Global Encephalitis Vaccines Market is projected to register a CAGR of 5.2% during the forecast period (2025-2030)
Who are the key players in Global Encephalitis Vaccines Market?
Valneva SE., Bharat Biotech, BIKEN, Pfizer Inc. and GlaxoSmithKline are the major companies operating in the Global Encephalitis Vaccines Market.
Which is the fastest growing region in Global Encephalitis Vaccines Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Encephalitis Vaccines Market?
In 2025, the North America accounts for the largest market share in Global Encephalitis Vaccines Market.
What years does this Global Encephalitis Vaccines Market cover?
The report covers the Global Encephalitis Vaccines Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Encephalitis Vaccines Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Global Encephalitis Vaccines Market Report
Statistics for the 2025 Global Encephalitis Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Encephalitis Vaccines analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
